Company intelligence / Profile preview
Cimeio Therapeutics
Cambridge, Massachusetts, United Statescimeio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Preclinical data shows their shielding technology works in vivo across multiple programs. Their CD117 shield results in no residual binding when paired with their CD117 antibody.
- Therapeutic areas
- ImmunologyRare DiseasesHematology
- Modalities
- Gene editingCell therapyImmunotherapyAntibody-drug conjugates (ADCs)CAR-T cells
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Kyowa KirinUniversity of PennsylvaniaPrime Medicine
Beyond the preview
Go deeper on Cimeio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cimeio Therapeutics.